Wyeth

Genetics Institute, Inc.

Medimmune Limited

Pfizer Corporation

Abbott Gmbh & Co Kg

Abbvie Inc.

Abbvie Deutschland Gmbh and Co Kg

Cambridge Antibody Technology Limited

Geertruida Machteld Veldman

Denise M O'Hara

Neil M Wolfman

Monique V Davies

Kristie Grove Bridges

Gray D Shaw

Samuel Goldman

Viia Valge-Archer

Angela Widom

Caroline S Russell

Ravindra Kumar

Dianne S Sako

Glenn R Larsen

Xiang-Yang Tan

Dale Anthony Cumming

Xiao-Jia Chang

Maximiliano Vasquez

Lioudmila Tchistiakova

Mary Collins

Boris Labkovsky

Jochen G Salfeld

Gary S Gray

Zehra Kaymakcalan

Michael White

Michael Roguska

Man Sung Co

Paul Sakorafas

Nicholas W Warne

Kimberly Ann Marquette

Beatriz M Carreno

Subhashis Banerjee

Thor Las Holtet

Daniel Edward Tracey

Elaine Joy Derbyshire

John Gawain Elvin

Sara Carmen

Michael Paskind

Alexander Robert Duncan

Abbie Cheryl Celniker

Andrea Knight

Bonita Rup

Amy Venturini

Stephen Smith

Sarah Leila Du Fou

Stuart Friedrich

Jing Li

Lynette A Fouser

Lisa-Anne Whittemore

Ralph Raymond Minter

Davinder Gill

Lisa Anne Collins-Racie

David C Lowe

Christopher John Corcoran

Edward Roland Lavallie

Riyez Karim

Tejvir S Khurana

Suzanne E Cohen

Albert George Thom

Angela Myles

Kening Song

Anne Field

Jane Aghajanian

Mary L Bouxsein

John Adam Nowak

William J Dunham, Legal Representative

Jose William Saldanha

Debra D Donaldson

Lori J Fitz

Laura Lin

Eric Feyfant

Kevin Delos Parris

Marion T Kasaian

Angela Kantor

Tania Shane

Amy Sze Pui Tam

Nancy L Wood

Joseph Lawrence Wooters

Xiao-jia Chang

Ray Camphausen

Debra D Pittman

Kathleen N Tomkinson

Viia Valge-archer

Denise O'hara

Lioudmila Gennadievna Tchistiakova

Jane (deceased) Aghajanian

Davinder S Gill

Albert B Thom

Kristie Grove-Bridges

Caroline Russell

Denise O'HARA

The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti-GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also provides for an immunoassay used to detect and quantitate GDF8. The disclosure also provides methods for diagnosing, preventing, ameliorating, and treating GDF8-associated disorders, e.g., degenerative orders of muscle, bone, and insulin metabolism. Finally, the disclosure provides pharmaceuticals for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.

Antibody to GDF8 and uses thereof

The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or insulin metabolism.

Isolated cell comprising a nucleic acid encoding antibody inhibitors of gdf-8 and uses thereof

The disclosure provides novel molecules related to growth and differentiation factor 8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also provides for an immunoassay used to detect and quantitate GDF8. The disclosure also provides methods for diagnosing, preventing, ameliorating, and treating GDF8 associated disorders, e.g., degenerative orders of muscle, bone, and insulin metabolism. Finally, the disclosure provides pharmaceuticals for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Human antibodies that bind the P40 subunit of human IL-12 and methods for using the same

The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), in particular human antibodies, and antibody fragments, including those that inhibit GDF-8 activity in vitro and/or in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle or bone, or disorders of insulin metabolism.

Neutralizing antibodies against GDF-8 and uses therefor

Methods of treatment using human antibodies that bind IL-12

Human antibodies that bind human interleukin-12

Isolated nucleic acid molecule encoding an antibody that reduces GDF-8 activity

The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.

Nucleic acid encoding antibody to human IL-22

A novel P-selectin ligand glycoprotein is disclosed, comprising the amino acid sequence set forth in SEQ ID NO:2 or by the amino acid sequence set forth in SEQ ID NO:4. DNA sequences encoding the P-selectin ligand protein are also disclosed, along with vectors, host cells, and methods of making the P-selectin ligand protein. Pharmaceutical compositions containing the P-selectin ligand protein and methods of treating inflammatory disease states characterized by P-selectin- and E-selectin-mediated intercellular adhesion are also disclosed.

P-selectin ligand protein

This application relates to antibodies, e.g., humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preventing, and/or treating a subject, e.g., a human patient, one or more IL-13-associated disorders, e.g., respiratory disorders (e.g., asthma); atopic disorders (e.g., allergic rhinitis); inflammatory and/or autoimmune conditions of the skin (e.g., atopic dermatitis), and gastrointestinal organs (e.g., inflammatory bowel diseases (IBD)), as well as fibrotic and cancerous disorders.

Antibodies against human interleukin-13 and uses therefor

Antibodies to human IL-22

Growing community of inventors

Sudbury, MA, United States of America

Geertruida Machteld Veldman